Interacción de Darunavir y cobicistat con Fluticasona y salmeterol
Darunavir y cobicistat con Fluticasona y salmeterol: ambas etiquetas de prescripción advierten sobre esta combinación con el lenguaje más contundente, como una contraindicación, una advertencia en recuadro o la indicación de evitarla.
No combinar sin la orientación de un prescriptor. El lenguaje de la etiqueta que aparece a continuación es el más contundente que usa la FDA.
Qué dicen las etiquetas de la FDA
De la etiqueta de Fluticasona y salmeterol (Fluticasone Propionate and Salmeterol) · vigente desde 2025-08-21
Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects.
Drug Interactions with Strong Cytochrome P450 3A4 Inhibitors The use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with Fluticasone Propionate/Salmeterol MDPI is not recommended because increased systemic corticosteroid and…
The use of strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with Fluticasone Propionate/Salmeterol MDPI is not recommended because increased systemic corticosteroid and increased cardiovascular adverse effects may occur.
Ritonavir : Fluticasone Propionate: A drug interaction trial with fluticasone propionate aqueous nasal spray in healthy subjects has shown that ritonavir (a strong CYP3A4 inhibitor) can significantly increase plasma fluticasone propionate exposure, resulting in significantly reduced serum cortisol concentrations [see Clinical Pharmacology (12.3)] .
Inhibitors of Cytochrome P450 3A4 Fluticasone propionate and salmeterol, the individual components of this product, are substrates of CYP3A4.
De la etiqueta de Darunavir y cobicistat (PREZCOBIX) · vigente desde 2026-02-01
Inhaled beta agonist: salmeterol ↑ salmeterol Co-administration with salmeterol is not recommended and may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia.
Corticosteroids: dexamethasone (systemic) Corticosteroids primarily metabolized by CYP3A: e.g. betamethasone budesonide ciclesonide fluticasone methylprednisolone mometasone triamcinolone ↓ darunavir ↓ cobicistat ↑ corticosteroids Co-administration with systemic dexamethasone or other systemic corticosteroids that induce CYP3A may result in loss of therapeutic…
Consider alternative corticosteroids.
Co-administration with corticosteroids (all routes of administration) of which exposures are significantly increased by strong CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression.
Alternative corticosteroids including beclomethasone, prednisone and prednisolone (for which PK and/or PD are less affected by strong CYP3A inhibitors relative to other steroids) should be considered, particularly for long-term use.
¿Toma algo más además de estos dos? Las interacciones se acumulan. Compruebe toda su lista de una vez; se queda en su navegador.
Abrir en el verificadorNo es un consejo médico. Interaction Checker cita el texto de las etiquetas de la FDA y las hojas informativas de los NIH. Que una interacción sea importante en su caso depende de las dosis, el momento de las tomas, la función renal y hepática y otras afecciones. Confírmelo con un farmacéutico o un prescriptor.